Document is current
Any future updates will be listed below
-
Authors
Laine, Anna https://orcid.org/0009-0007-2738-4242
Muilu, Paula https://orcid.org/0000-0003-2375-705X
Kautiainen, Hannu https://orcid.org/0000-0003-0786-0858
Rantalaiho, Vappu https://orcid.org/0000-0002-7470-3070
-
Funding
Funding for this research was provided by:
Tampere University
- License Information
-
More Information
Article History
Received: 13 May 2026
Accepted: 17 June 2026
First Online: 6 July 2026
Declarations
Conflict of interest: A.L. reports two congress trips from AbbVie outside the submitted work. P.M. reports a one-time consulting assignment for Johnson & Johnson and a congress trip from Orion Pharma, Boehringer Ingelheim, and Johnson & Johnson outside the submitted work. V.R. reports speaker’s honoraria from Novartis, AbbVie, Viatris, BMS, Johnson & Johnson, and Medac and participation on an advisory board for Lilly outside the submitted work. H.K. declares no conflicts of interest.
Ethical approval: Authorization to access and use the national registers was obtained from the SII. According to Finnish legislation, ethical approval is not required for register-based studies in which study subjects are not contacted.
Disclaimer: Authors certify that this work is original, has not been published previously, or generated by AI. Microsoft Copilot was used for language editing. Authors reviewed and revised the text and take full responsibility for the final manuscript.
